" class="no-js "lang="en-US"> Parker Institute for Cancer Immunotherapy (PICI) - Medtech Alert
Tuesday, October 01, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Parker Institute for Cancer Immunotherapy (PICI) | Pharmtech Focus

Parker Institute for Cancer Immunotherapy (PICI)

About Parker Institute for Cancer Immunotherapy (PICI)

Parker Institute for Cancer Immunotherapy (PICI)
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.

Related Story

Diseases

 LumaBridge and Parker Institute for Cancer Immunotherapy Announce Strategic Alliance to Streamline Immunotherapy Development | Pharmtech Focus

LumaBridge and Parker Institute for Cancer Immunotherapy Announce Strategic Alliance to Streamline Immunotherapy Development

August 25 2022

LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and […]